← Back to all trials
Not Yet Recruiting
NCT05727800
A Phase 1, First-in-human Study of VX-668
Conditions: Alpha-1 Antitrypsin Deficiency
Sex: All
Ages: 18 Years – 55 Years
Healthy volunteers: 1
Phase: PHASE1
Enrollment: 114
Sponsor: Vertex Pharmaceuticals Incorporated
Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of VX-668 at various doses.
Eligibility Criteria
Key Inclusion Criteria:Participants of age between 18 to 55 years (inclusive)Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m^2)A total body weight of more than (>)50 kgNonsmoker or ex-smoker for at least 3 months before screeningKey Exclusion Criteria:Any condition possibly affecting drug absorptionFemales of childbearing potentialOther protocol defined Inclusion/Exclusion criteria may apply.
Source: ClinicalTrials.gov (NCT05727800). StuddyBuddy aggregates publicly available trial information.
